Vir Biotechnology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vir Biotechnology, Inc. - overview
Established
2016
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
Based in the US, Vir Biotechnology, Inc. is a biotechnology firm focused on developing innovative therapies aimed at addressing infectious diseases and oncology through advanced antibody technologies. Vir Biotechnology, Inc. was founded in 2016 and operates out of San Francisco, US.
The company specializes in the development of therapies targeting infectious diseases and cancer using its own proprietary technologies. The founder, Vicki Sato, has a background in biotechnology and has previously been involved in founding other companies. The company has raised a total of USD 299. 99 mn, with the latest funding round, a Grant, yielding USD 50.
00 mn from the Biomedical Advanced Research and Development Authority. Vir has engaged in 7 total funding deals, with its most recent deal occurring on July 7, 2020. Vir Biotechnology is dedicated to creating advanced therapies utilizing its next-generation antibody platform and the proprietary PRO-XTEN™ protease-releasable masking technology. The company’s initiatives focus on chronic hepatitis delta, COVID-19, and Ebola, with products designed to enhance immune responses.
Its offerings are primarily targeted towards healthcare providers and institutions in North America and Europe, designed to meet the needs of patients affected by these health challenges. In the most recent fiscal year 2024, Vir Biotechnology reported a revenue of USD 74. 21 mn, alongside an EBITDA of USD -572. 61 mn, indicating a significant investment in its developmental strategies.
Vir Biotechnology plans to launch upcoming products developed from its advanced antibody platform and PRO-XTEN™ technology, although specific release dates have not been disclosed. The company is also targeting expansion into new international markets, with strategic efforts focused on Europe and Asia. The funding obtained from the most recent deal in July 2020 will support the advancement of these initiatives, enabling the company to enhance its R&D capabilities and accelerate the development of its therapeutic candidates.
Current Investors
Alta Partners, ARCH Venture Partners, Altitude Life Science Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.vir.bio
Company Stage
Mature
Total Amount Raised
Subscriber access only
Vir Biotechnology, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Executive Chairman | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.